Clinical Development Readiness

Q: What is a Target Product Profile and why does it matter in rare disease?

A Target Product Profile (TPP) is a strategic document that defines what a drug needs to achieve clinically and commercially to be viable — the minimum acceptable profile and the ideal profile. In rare disease, the TPP is especially important because regulatory authorities, including the EMA and FDA, expect to see a clearly articulated TPP early in development. It disciplines the programme around what actually matters to patients, clinicians, and regulators, and helps avoid costly development pivots later. CortexBio supports clients in developing and refining TPPs grounded in real-world rare disease clinical and patient-reported evidence.

Q: How important is natural history study design in rare disease clinical development?

Natural history studies are often critical in rare disease development because they generate the baseline data needed to understand disease progression, define meaningful clinical endpoints, and design comparator arms when randomised controlled trials are not feasible. Regulators increasingly expect robust natural history data before approving trials in ultra-rare conditions. CortexBio advises on natural history study design, data collection frameworks, and the integration of natural history evidence into regulatory dossiers and clinical development plans.

Q: When should a biotech company engage a clinical development readiness consultant?

The highest-value point of engagement is before Phase 1 or Phase 2 planning begins — when there is still time to shape the development strategy rather than course-correct it. Companies typically benefit most when they have a promising preclinical or early clinical asset and need to define the regulatory pathway, identify the right patient population, design robust endpoints, and align the clinical strategy with what regulators and payers will ultimately require. Engaging too late — after a trial is designed and underway — significantly limits the strategic options available.

Q: How does CortexBio reduce risk in rare disease clinical programmes?

CortexBio reduces clinical development risk by applying experienced strategic judgement at the points where poor decisions have the highest cost. This includes rigorous patient population definition (getting this wrong is the most common cause of rare disease trial failure), endpoint selection aligned with regulatory expectations, early regulatory engagement strategy, and realistic assessment of what a development programme can and cannot achieve given the available evidence base. The goal is not to add process — it is to identify the specific gaps that will cause problems at regulatory review and resolve them before they become expensive.

Overview

CortexBio offers strategic guidance and hands-on support to optimise your clinical development journey, leveraging specialised expertise in rare and metabolic diseases. We help companies navigate the complex landscape of clinical development, from early planning through execution and regulatory submission.

Our Approach

We strike a balance between scientific rigour and practical implementation to create development plans that maximise efficiency and minimise risk. Our services include:

· Target Product Profile Development: Create comprehensive Target Product Profiles (TPPs) that align your clinical development with commercial goals and patient needs.

· Clinical Development Strategy: Design optimal development pathways that balance scientific, regulatory, and commercial considerations.

· Study Design Optimisation: Develop innovative clinical trial designs tailored to rare and metabolic diseases, including adaptive trials and platform approaches.

· Chemistry, Manufacturing, and Controls (CMC) Readiness: Ensure your CMC strategy keeps pace with accelerated clinical timelines through the FDA's CDRP program and other approaches.

Benefits

· Accelerated development timelines through strategic planning and regulatory alignment

· Enhanced probability of success through optimised trial designs

· Improved resource allocation through clear development roadmaps

· Greater alignment between clinical, regulatory, and commercial objectives

Why CortexBio

Our "metabolic mosaic" approach uniquely positions us to identify shared mechanisms between rare diseases and ageing, thereby opening up novel clinical development strategies. Dr. Martini-Drew's experience leading cross-functional teams in global pharmaceutical companies provides practical insights into successful clinical development approaches.

Last updated: April 2026

Frequently Asked Questions

What is clinical development readiness for rare diseases?
Clinical development readiness means ensuring that a rare disease drug development programme has the scientific, strategic, and operational foundations in place before entering clinical trials. For rare diseases this is particularly demanding: patient populations are small, trial design is complex, natural history data is often limited, and regulatory pathways require early and careful navigation. CortexBio helps companies assess whether their programme is genuinely trial-ready and identify the gaps that need closing before committing to expensive clinical investment.

What is a Target Product Profile and why does it matter in rare disease?
A Target Product Profile (TPP) defines what a drug needs to achieve clinically and commercially to be viable. In rare disease, the TPP is especially important because regulators expect to see it early in development. It disciplines the programme around what actually matters to patients, clinicians, and regulators — and helps avoid costly development pivots later. CortexBio supports clients in developing and refining TPPs grounded in real-world rare disease evidence.

How important is natural history study design in rare disease development?
Natural history studies are often critical because they generate the baseline data needed to understand disease progression, define meaningful clinical endpoints, and design comparator arms when randomised controlled trials are not feasible. Regulators increasingly expect robust natural history data before approving trials in ultra-rare conditions. CortexBio advises on natural history study design and the integration of this evidence into regulatory dossiers.

When should a biotech company engage a clinical development readiness consultant?
The highest-value point is before Phase 1 or Phase 2 planning begins — when there is still time to shape the development strategy rather than course-correct it. Companies benefit most when they have a promising early-stage asset and need to define the regulatory pathway, identify the right patient population, design robust endpoints, and align clinical strategy with what regulators and payers will ultimately require.

How does CortexBio reduce risk in rare disease clinical programmes?
CortexBio reduces risk by applying experienced strategic judgement at the points where poor decisions have the highest cost: patient population definition, endpoint selection aligned with regulatory expectations, early regulatory engagement strategy, and realistic assessment of what a development programme can achieve given the available evidence. The goal is to identify the specific gaps that will cause problems at regulatory review — and resolve them before they become expensive.

Home